Eton Pharmaceuticals, Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Eton Pharmaceuticals reported Q2 2026 product sales of $37.6M (99% YoY growth vs. $18.9M in Q2 2025), driven by HEMANGEOL relaunch with 95% patient conversion by end-June and portfolio growth. The company raised full-year 2026 revenue guidance to exceed $145M (from $120M+) and expects ≥35% Adjusted EBITDA margin (from ≥30%). Eton acquired late-stage ASN-001 for infantile hemangioma treatment (expected NDA submission H2 2027), acquired IMPAVIDO commercialization rights (launching September 2026), and received FDA Fast Track designation for AMGLIDIA. Q2 GAAP net income was $11.6M ($0.35/diluted share); Adjusted EBITDA was $16.2M (43% margin). Cash position $26.8M as of June 30, 2026.
Why this rating
Strong execution: 99% revenue growth and margin expansion material to $360.6M market cap. Guidance raise ($145M revenue ~40% of market cap annually) and pipeline expansion (ASN-001, AMGLIDIA Fast Track) signal durable growth. However, profitability still nascent, debt outstanding ($27.9M), and pipeline success unproven.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.